Last updated: February 13, 2026
Market Analysis and Price Projections for NDC 60219-1674
Overview of the Drug
- NDC 60219-1674 identifies Atezolizumab, marketed as Tecentriq. It is an immune checkpoint inhibitor used primarily for multiple cancer indications, including non-small cell lung cancer (NSCLC), urothelial carcinoma, and others.
- Approval Timeline: First approved by the FDA in May 2016 for metastatic NSCLC, with subsequent approvals expanding its indications.
- Mechanism: It inhibits PD-L1, restoring immune system response to tumors.
Market Landscape
- The global oncology immunotherapy market remains highly competitive, dominated by PD-1 and PD-L1 inhibitors.
- Key competitors include Pembrolizumab (Keytruda), Nivolumab (Opdivo), Atezolizumab (Tecentriq), Durvalumab (Imfinzi), and others.
- Market Size & Growth:
- Estimated to reach $288 billion by 2030 from $113 billion in 2022, driven by increased cancer prevalence and immune therapy approvals (Fortune Business Insights, 2022).
- PD-L1 inhibitors like Tecentriq account for approximately 20% of the immunotherapy market share.
Sales and Revenue Trends
- 2019-2022 Revenue:
- 2019: ~$550 million globally.
- 2020: ~$770 million.
- 2021: ~$1.4 billion.
- 2022: Estimated exceeding $1.8 billion.
- Growth Drivers:
- Expanded indications.
- Increased adoption in first-line settings.
- Strong clinical trial results supporting use across multiple cancers.
Market Penetration and Adoption
- Physician Adoption:
- Growing acceptance among oncologists, driven by positive trial outcomes.
- Accessibility varies based on reimbursement policies and regional approval.
- Reimbursement & Coverage:
- Covered by major insurance providers in the US; reimbursement practices influence sales volume.
Price Analysis
- List Price (US):
- Atezolizumab (Tecentriq) is priced around $12,500 to $13,000 per 1200 mg dose (based on average wholesale price, AWP).
- Cost Dynamics:
- Dosing varies by indication, typically 1200 mg every 3 weeks.
- Cost per treatment course generally ranges between $70,000 to $90,000.
- Pricing is aligned with other PD-L1 inhibitors, exhibiting slight variations based on negotiated discounts and rebates.
Future Price Projections
- Market Trends:
- Price stabilization or slight increases due to inflation, manufacturing costs, and new indications.
- Competitive pressure may influence price reductions or value-based pricing strategies.
- Estimated Price Range (Next 5 Years):
- Predicted to remain within $12,500–$14,000 per dose.
- Volume growth expected to offset modest pricing pressures, sustaining revenue growth.
- Potential for price adjustments based on outcome-based reimbursement agreements and biosimilar developments.
Biosimilar Impact
- Potential Biosimilars:
- No biosimilars approved yet as of 2023.
- Pending patent expirations could lead to competitive biosimilar entry post-2030, possibly driving prices down.
- Impact on Market Share:
- Biosimilars could reduce Tecentriq's price by 20–40% upon entry.
- Fragmentation may alter market dynamics, requiring pricing realignments.
Regulatory & Policy Factors
- Pricing Regulation Trends:
- US policymakers scrutinize high-cost cancer drugs.
- Value-based agreements are increasingly adopted, linking reimbursement to patient outcomes.
- Reimbursement Trends:
- Medicare and private payers aim to maximize value, influencing net prices.
Key Takeaways
- Market position: Tecentriq maintains a significant share of the PD-L1 inhibitor segment, with expanding indications driving sales.
- Sales trajectory: Revenue is projected to grow at a CAGR of approximately 20% over the next five years, assuming continued approval and uptake.
- Pricing outlook: Price per dose is stabilized around $12,500–$14,000, with potential downward pressure post-biosimilar entry.
- Competitive landscape: Market dynamics hinge on clinical results, reimbursement policies, and biosimilar developments.
- Policy impact: Regulatory focus on drug pricing could influence future net prices more than list prices.
FAQs
1. What are the main drivers of Tecentriq’s market growth?
Expansion of indications, clinical trial success, and increasing adoption in frontline treatments.
2. How does Tecentriq’s price compare with its competitors?
It is generally priced slightly higher than Nivolumab and Pembrolizumab on a per-dose basis but reflects its market positioning and reimbursement terms.
3. What factors could affect Tecentriq’s future pricing?
Biosimilar competition, regulatory policies, outcome-based reimbursement agreements, and inflation.
4. Will biosimilars significantly reduce Tecentriq’s price?
Likely, with potential price reductions of 20–40% once biosimilars enter the market after patent expiry.
5. How does the high cost impact market penetration?
Reimbursement and coverage policies limit access, but high efficacy and expanded indications continue to drive adoption.
References
[1] Fortune Business Insights, "Global Oncology Immunotherapy Market," 2022.
[2] IQVIA, National Prescription Audit, 2022.
[3] FDA, "Atezolizumab (Tecentriq) Approval Details," 2016.
[4] SSR Health, "Drug Pricing and Revenue Data," 2022.
